et al.16 They showed that the 5-year survival rates of TMPRSS4-positive and negative patients with stages II and III GC were approximately 40% and 80%, respectively, further proposing that TMPRSS4 expression can be applied as an indicator of poor prognosis in GC patients. This evidence concerns the gene TMPRSS4 and gastric cancer.